Key result
An inactivated CA16 whole-virus vaccine provided full protection to gerbils against lethal doses of CA16 strains at doses of 40 U and above.
Why the study?
Does an inactivated CA16 whole-virus vaccine protect young gerbils against lethal doses of CA16?
Does an inactivated CA16 whole-virus vaccine protect young gerbils against lethal doses of CA16?
Absolute Event Rate: 100% vs 0%
p-value: p=<0.01
Gerbils up to 21 days old serve as a suitable animal model for CA16 infection and vaccine evaluation, as demonstrated by full protection from an inactivated whole-virus vaccine.
Validates inactivated CA16 vaccine in gerbil model; leaves open human translation and clinical trials.
Coxsackievirus A16 (CA16) is one of the major pathogens associated with human hand, foot, and mouth disease (HFMD) in the Asia-pacific region. Although CA16 infections are generally mild, severe neurological manifestations or even death has been reported. Studies on CA16 pathogenesis and vaccine development are severely hampered because the small animal models that are currently available show major limitations. In this study, gerbils (Meriones unguiculatus) were investigated for their suitability as an animal model to study CA16 pathogenesis and vaccine development. Our results showed that gerbils up to the age of 21 days were fully susceptible to CA16 and all died within five days post-infection. CA16 showed a tropism towards the skeletal muscle, spinal cord and brainstem of gerbils, and severe lesions, including necrosis, were observed. In addition, an inactivated CA16 whole-virus vaccine administrated to gerbils was able to provide full protection to the gerbils against lethal doses of CA16 strains. These results demonstrate that gerbils are a suitable animal model to study CA16 infection and vaccine development.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2016) studied Coxsackievirus A16 (CA16) infection. Inactivated CA16 whole-virus vaccine vs. PBS (control) was evaluated on Survival after lethal challenge with CA16 (p=<0.01). An inactivated CA16 whole-virus vaccine provided full protection to gerbils against lethal doses of CA16 strains at doses of 40 U and above.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: